Alzheimer’s disease (AD) is a progressive neurodegenerative disease that results in cognitive dysfunction. It has several hallmark pathological features including β-amyloid plaques, neurofibrillary tangles, and neuronal cell death that lead to functional deterioration (Schneider and Sari 2014). Although there are currently no treatments to reverse or even slow the progression of AD, medications are aimed at temporarily reducing cognitive dysfunction, such as memory loss and confusion. Current medications primarily target increasing acetylcholine (cholinesterase inhibitors) or blocking glutamate (NMDA receptor antagonists).

In AD, morphological and structural changes occur in the brain with widespread involvement of the hippocampus, association cortices, amygdala, nucleus basalis of Meynert (nBM), and other structures. Alterations in the hippocampus and entorhinal cortex (EC) occur before cognitive symptoms and correlate with the severity of the disease (Risacher et al. 2009). In addition to structural changes, there is aberrant functional activity. In early AD, for example, there is evidence for a reduction in glucose metabolism in the temporal lobe and posterior cingulate gyrus (Smith et al. 1992; Minoshima et al. 1997).

There is increasing evidence that AD is associated with network dysfunction. More specifically, there are perturbations in the circuit of Papez (Sperling et al. 2010), default mode network (Greicius et al. 2004), and salience network (Zhou et al. 2010). In AD, there is evidence for reduced functional connectivity in the circuit of Papez (Li et al. 2014) and default mode network but increased connectivity in the salience network (Zhou et al. 2010). These alterations in connectivity are associated with deficits in working memory and cognition.

Deep brain stimulation (DBS) is an electrical form of neuromodulation that enables for spatially and temporally specific stimulation. Historically, this treatment modality has been used in movement disorders, such as Parkinson’s disease, essential tremor, and dystonia; however, more recently, it has been explored in cognitive and psychiatric disorders, including obsessive–compulsive disorder, depression, and epilepsy. Here, we describe the evolution of our translational and clinical research using DBS for AD.

ENGAGING THE CIRCUIT OF PAPEZ WITH DEEP BRAIN STIMULATION

During bilateral hypothalamic DBS surgery for obesity, we serendipitously discovered that as an electrode was being advanced toward the hypothalamus, perifornicial stimulation (3.0 V, 60 µsec pulse width, and 130 Hz) triggered autobiographical memories intraoperatively (Hamani et al. 2008). After 3 wk of bilateral hypothalamic stimulation, using stimulation parameters that did not induce overt memory, sensory, or autonomic effects (2.8 V, 60 µsec pulse width, and 130 Hz), the patient showed improvements in neuropsychological assessments (California Verbal Learning Test and Spatial Associative Learning Test). Two months after implantation, the patient underwent a battery of memory tests with stimulation identified to elicit memories intraoperatively (3.0 V, 60 µsec pulse width, and 130 Hz). Here, stimulation enhanced hippocampal-dependent recollection but not familiarity-based recognition.

To confirm that stimulation was activating the Papez circuit, standardized low-resolution electromagnetic to-
mography was conducted after 1 mo of stimulation. During sLORETA, 3 Hz of unilateral stimulation activated the ipsilateral hippocampal and parahippocampal formations. Taken together, these findings suggested that it is possible to engage the circuit of Papez with fornical DBS and enhance hippocampal-dependent memory.

FORNICAL DBS FOR AD

The hallmark symptoms of AD are functional impairments in cognitive and memory functions. Given the potentially beneficial effects of stimulation on memory and activation of the Papez circuit, we proposed a six-patient phase 1 clinical trial using fornical DBS in mild AD patients. In this study, patients received 1 yr of continuous bilateral stimulation (130 Hz, 3–3.5 V, 90 µsec pulse width) (Laxton et al. 2010). At 12 mo, half the patients showed a slight worsening in the Alzheimer’s Disease Assessment Scale, Cognitive subscale (ADAS-Cog), whereas the other half showed a mild improvement. Interestingly, the patient who had the most vivid intraoperative experiential recollections had the greatest improvement in ADAS-Cog scores. Moreover, there may have been a less than expected decline in Mini-Mental Status Exam (MMSE) scores over the 12-mo period.

After 1 yr, sLORETA of these six patients showed activation of memory circuits (frontal-temporal-parietal-striatal-thalamic and frontal-temporal-parietal-occipital-hippocampal networks) and the default mode network, including the hippocampus, parahippocampal gyrus, cingulate gyrus, and precuneus. AD is associated with decreased glucose metabolism in the temporal and parietal regions (Smith et al. 1992; Minoshima et al. 1997). Although anticholinergic medications have shown transient increases in glucose cerebral metabolism, 1 yr of DBS resulted in persisting increased temporal and parietal glucose metabolism in regions relatively spared in AD (Figs. 1 and 2; Laxton et al. 2010; Smith et al. 2012). Interestingly, increased metabolism was correlated with improvements in cognition, memory, and quality of life (Smith et al. 2012).

AD is characterized by atrophy in several brain structures. Of note, there is a correlation between site-specific volumetry (lower subiculum volume and fornix integrity) and cerebrospinal fluid biomarkers (decreased CSF Aβ and tau levels) as well as associated lower cognitive scores (Tardif et al. 2018). In addition to activating the Papez circuit, we hypothesized that fornical DBS may influence the progressive atrophy characteristic of AD. To our surprise, in the two patients who had the best clinical outcomes, there were bilateral increases in hippocampal volume after 1 yr of stimulation. Overall, hippocampal, fornix, and mammillary body atrophy was slower in the six DBS patients relative to age-matched AD controls, suggesting network-wide activation (Sankar et al. 2015).

Based on these findings, a 12-mo, double-blind, randomized controlled feasibility study was performed (ADVANCE trial). 42 patients with mild AD (Clinical Dementia Rating Sum of Boxes [CDR-SB] of 0.5 or 1) underwent bilateral fornical DBS implantation (Lozano et al. 2016).

Figure 1. A composite positron emission tomography of the five Alzheimer’s patients at baseline (1 mo before surgery), 1 mo after, and 12 mo after continuous bilateral fornical/hypothalamic deep brain stimulation as well as six age-matched health controls. There was increased metabolism in the temporal, posterior cingulate, and parietal regions both at 1 mo and sustained at 12 mo. The flame scale demonstrates fluorodeoxyglucose use per 100 g tissue/min, with red indicating the highest values and blue the lowest values. (MTG) Middle temporal gyrus, (PCg) posterior cingulate gyrus, (ITG) inferior temporal gyrus, (FG) fusiform gyrus. (Reprinted from Laxton et al. 2010, with permission from John Wiley and Sons.)
In this trial, patients were randomized to continuous bilateral stimulation (130 Hz, 3–3.5 V, 90 µsec pulse width) or sham stimulation for 12 mo. There were no significant differences between the two groups with respect to primary outcomes, such as ADAS-Cog 13 and CDR-SB scores, or secondary clinical outcomes (California Verbal Learning Test—Second Edition, Alzheimer’s Disease Cooperative Study Activities of Daily Living Scale and Neuropsychiatric Inventory).

Although there was no significant difference in primary or secondary outcomes, a post hoc analysis showed that younger patients receiving stimulation (<65 yr) had a significant worsening in ADAS-Cog-13 and CDR-SB scores compared to sham stimulation. In contrast, older patients receiving stimulation (≥65 yr) appeared to have less decline than sham stimulation patients.

Interestingly, the <65-yr-old group showed further decreased PET cerebral glucose metabolism after 1 yr of stimulation within regions typically affected in AD, such as the temporal and parietal regions. In contrast, the ≥65-yr-old cohort showed increased metabolism within the temporal and parietal regions with stimulation after 6 mo (Lozano et al. 2016). Additionally, stimulation also increased metabolism in regions that are relatively spared in AD, such as sensory and motor cortex as well as the cerebellum.

After the first year of randomization, all patients underwent bilateral fornix stimulation. Although the study showed that fornix DBS had a favorable safety profile, the study was not powered to determine a clinical benefit. However, it suggested a possible benefit in the older population (>65 yr) (Leoutsakos et al. 2018). As such, we are in the process of enrolling a phase 3 multicenter clinical trial across North America and Europe to evaluate the potential benefits of bilateral fornixal DBS in the older cohort (>65 yr). This randomized control trial plans to enroll 150 patients to either fornixal or no bilateral fornixal stimulation over the course of 12 mo.

**OTHER DBS TARGETS FOR AD**

Subsequent DBS trials have examined other targets including the nbM and the ventral capsule/ventral striatum (VC/VS). The nbM is a group of cholinergic neurons in the substantia innominata of the basal forebrain that are particularly susceptible to neurodegeneration in AD (Arendt et al. 1983). Furthermore, nonhuman primate intermittent nbM DBS resulted in improved working memory that was dependent on cholinergic function (Blake et al. 2017). In a six-patient pilot study of nbM DBS, four of the six patients were considered responders (relatively stable ADAS-Cog and MMSE scores) (Kuhn et al. 2015). Stimulation parameters ranged from 10 to 20 Hz frequency, 90–150 µsec pulse width, and 2.0–4.5 V. Consistent with the fornixal DBS subgroup analysis, patients with greater fronto-parieto-temporal cortical thickness (i.e., less advanced atrophy) had a greater cognitive benefit from nbM DBS (Baldermann et al. 2018).

The VC/VS has projections to the dorsomedial and orbital prefrontal cortices, which are important in executive function. As such, VC/VS DBS was performed in three

---

**Figure 2.** Voxel-wise comparisons of positron emission tomography of glucose metabolism. (A) Prior to DBS, AD patients show decreased metabolism compared to controls. (B) One month of bilateral fornixal/hypothalamic DBS, the temporal regions (left middle and bilateral inferior temporal gyri), parietal cortical regions (bilateral fusiform gyri and superior parietal lobules, right precuneus, left posterior cingulate gyrus, and inferior parietal lobule), sensory and motor (left pre- and postcentral gyrus, bilateral lingual and bilateral cuneus gyri) and cerebellar regions (left medulla), and cerebellum (bilateral dentate and culmen) showed significant increases in metabolism. The anterior cortical areas (bilateral anterior cingulate, right medial and middle frontal and bilateral precentral gyri) and subcortical areas (left caudate and thalamus [medial dorsal nuclei]) showed decreased metabolism. (C) After 12 mo of DBS, these effects on metabolism were sustained. (Reprinted from Laxton et al. 2010, with permission from John Wiley and Sons.)
AD patients with less cognitive decline than age-matched controls over at least an 18-mo period. FDG-PET imaging was consistent with frontal cortical engagement (Scharre et al. 2018).

**MECHANISM OF DBS FOR AD**

Although fornix DBS has been shown to functionally engage the hippocampus, the mechanism of DBS is still not completely understood. Rodent studies show that fornix DBS can improve both hippocampal-dependent and hippocampal-independent memory (Zhang et al. 2015). Interestingly, there is evidence that the effects of fornix DBS on memory are not dependent on the frequency of stimulation but are dependent on the current levels (Heschem et al. 2013). Based on the observation that two of the six patients had enlargement of their hippocampi (as opposed to expected atrophy) (Sankar et al. 2015), there have been a number of rodent studies that have shown that electrical stimulation of limbic structures can promote adult neurogenesis, including EC stimulation (130 Hz, 90 µsec pulse width, 50 µA) (Stone et al. 2011; Mann et al. 2018) and anterior thalamic nucleus stimulation (Toda et al. 2008; Encinas et al. 2011). Interestingly, fornix DBS (130 Hz, 9 μsec pulse width, 2.5 V) results in increased expression of neurotrophic factors (BDNF, VEGF) and markers of synaptic plasticity (GAP-43, synaptophysin, α-synuclein [Gondard et al. 2015]).

The EC and thalamus have also been posited as potential DBS targets (Arrieta-Cruz et al. 2010). EC DBS has also been shown to improve behavior in AD rodent models. In a TgCRND8 (Tg) transgenic mouse model expressing human amyloid precursor protein harboring the Swedish and Indiana familial AD mutations, EC DBS rescued contextual fear and spatial memory as well as a decreased plaque load. Of note, the memory enhancement emerged gradually and was specific to hippocampal-dependent memory (Xia et al. 2017). Thalamic DBS has also been shown to improve hippocampal-dependent short-term memory in the Tg transgenic mouse as well (Arrieta-Cruz et al. 2010). Interestingly, a rodent study comparing EC, thalamic, and fornix DBS showed that EC and fornix DBS improved hippocampal-dependent memory more robustly than thalamic DBS. Moreover, EC and fornix DBS also had beneficial effects on hippocampal-independent recognition memory. Importantly, EC, thalamic, and fornix DBS did not result in increased anxiety or locomotor behaviors (Zhang et al. 2015).

There is also evidence that chronic EC DBS in a triple transgenic mouse model (3xTg-AD) or chemically induced synaptic stimulation of an in vitro culture of the EC in the 3xTg-AD model can reduce the accumulation of pathological forms of Tau via autophagosomes and lysosomes (Akwa et al. 2018). Interestingly, chronic inhibition of synaptic activity increased tau accumulation. Additionally, EC DBS reduces β-amyloid plaques, CA-1 cellular β-amyloid-42 levels, and cortical and hippocampal tau (Mann et al. 2018).

**CONCLUSION**

Despite the fact that DBS for AD has had varying results, there is preclinical and clinical evidence that fornix DBS engages networks important in memory and may affect AD-associated hippocampal atrophy. The phase 2 ADvance trial suggests that older patients may benefit from fornix DBS, whereas younger patients do not have cognitive benefits. The upcoming phase 3 clinical trial involving an exclusively older patient cohort will help to determine the effectiveness of fornix DBS on cognition and disease progression; however, it is important to understand why only a subset of patients would respond to treatment.

Further work is necessary to identify the effects of stimulation on sustained structural and functional changes and their potential relationship to treatment response. DBS stimulation parameters are currently informed by movement disorder pathology; however, engaging memory networks may need different stimulation parameters (i.e., theta, theta-burst stimulation). There is no evidence for network engagement and structural effects, suggesting the benefits of continuous stimulation. However, the ideal stimulation parameters for cognition may not require continuous stimulation. In fact, constant stimulation may interfere with normal cognition. As evidenced by variable responses to medications and stimulation, tailored treatments are necessary for individuals. Current DBS technology allows for responsive neurostimulation. Thus, identifying patient-specific electrophysiological biomarkers will be potentially important for tailoring stimulation.

The underlying mechanism of DBS for AD is still not known. Although DBS is able to target specific structures, with advances in technology, such as optogenetics, sonogenetics, and magnetogenetics, it is now possible to evaluate the effects of cell type–specific stimulation in a spatially and temporally relevant manner. Understanding the effects of stimulation on the underlying disease process will also help to inform stimulation parameters and targets. Similarly, identifying and creating better animal models will help with the difficulties in translating these findings to human clinical trials.

Taken together, DBS for AD remains a potentially promising new treatment for a devastating disease. Although it is safe in patients with AD, future studies will help to determine its efficacy and potential as an adjunctive treatment modality.

**REFERENCES**

Akwa Y, Gondard E, Mann A, Capetillo-Zarate E, Alberdi E, Matute C, Marty S, Vaccari T, Lozano AM, Baulieu EE, et al. 2018. Synaptic activity protects against AD and FTD-like pathology via autophagic-lysosomal degradation. *Mol Psychiatry* 23: 1530–1540. doi:10.1038/mp.2017.142

Arendt T, Bigl V, Arendt A, Tennstedt A. 1983. Loss of neurons in the nucleus basalis of Meynert in Alzheimer’s disease, paralysis agitans and Korsakoff’s disease. *Acta Neuropathol* 61: 101–108. doi:10.1007/BF00697388

Arrieta-Cruz I, Pavlides C, Pasinetti GM. 2010. Deep brain stimulation in midline thalamic region facilitates synaptic transmis-
sion and short term memory in a mouse model of Alzheimer’s disease. *Transl Neurosci* 1: 188–194.

Baldner, C., Koster, H.A., Köster, P., Horn, A., Freund, H.J., Zilles, K., Sturm, V., Visser-Vandewalle, V., Jessen, F., et al. 2018. Neuroanatomical characteristics associated with response to deep brain stimulation of the nucleus basalis of Meynert for Alzheimer’s disease. *Neuromodulation* 21: 184–190. doi: 10.1111/ner.12626

Blake DT, Terry AV, Plagenhoef M, Constantinidis C, Liu R. 2017. Postoperative changes in glucose metabolism of basalis of Meynert to impact treatment of Alzheimer’s disease. *Comm Integr Biol* 10: e1389359. doi: 10.1080/19420889.2017.1389359

Encinas JM, Hamani C, Lozano AM, Enikolopov G. 2011. Neurogenic hippocampal targets of deep brain stimulation. *J Comp Neurol* 519: 6–20. doi: 10.1002/cne.22503

Gondard E, Chau HN, Mann A, Tierney TS, Hamani C, Kalia SK, Lozano AM. 2015. Rapid modulation of protein expression in the rat hippocampus following deep brain stimulation of the fornix. *Brain Stimul* 8: 1058–1064. doi: 10.1016/j.brs.2015.07.044

Greicius MD, Srivastava G, Reiss AL, Menon V. 2004. Default-mode network activity distinguishes Alzheimer’s disease from healthy aging: evidence from functional MRI. *Proc Natl Acad Sci* 101: 4637–4642. doi: 10.1073/pnas.0308627101

Hamani C, McAndrews MP, Cohn M, Oh M, Zumsteg D, Shapiro CM, Wennberg RA, Lozano AM. 2008. Memory enhancement induced by hypothalamic/fornix deep brain stimulation. *Ann Neurol* 63: 119–123. doi: 10.1002/ana.21295

Heschl S, Lim LW, Jahanshahi A, Steinbusch HW, Prickaerts J, Blokland A, Temel Y. 2013. Deep brain stimulation of the fornical area enhances memory functions in experimental dementia: the role of stimulation parameters. *Brain Stimul* 6: 72–77. doi: 10.1016/j.brs.2012.01.008

Kuhn J, Hardencacke K, Lenartz D, Gruender T, Ullsperger M, Bartsch C, Mai JK, Zilles K, Bauer A, Matusch A, et al. 2015. Deep brain stimulation of the nucleus basalis of Meynert in Alzheimer’s dementia. *Mol Psychiatry* 20: 353–360. doi: 10.1038/mp.2014.32

Laxton AW, Tang-Wai DF, McAndrews MP, Zumsteg D, Wennberg R, Keren R, Wherrett J, Naglie G, Hamani C, Smith GS, et al. 2010. A phase I trial of deep brain stimulation of memory circuits in Alzheimer’s disease. *Ann Neurol* 68: 521–534. doi: 10.1002/ana.22089

Leoutsakos JS, Yan H, Anderson WS, Asaad WF, Baltuch G, Burke AE, Chakravarty MM, Drake KE, Foote KD, Fosdick L, et al. 2018. Deep brain stimulation targeting the fornix for mild Alzheimer Dementia (the ADVance trial): a two year follow-up including results of delayed activation. *J Alzheimers Dis* 64: 597–606. doi: 10.3233/JAD-180121

Li W, Antuono PG, Xie C, Chen G, Jones JL, Ward BD, Singh SP, Frankzak MB, Goveas JS, Li SJ. 2014. Abrerrant functional connectivity in Papez circuit correlates with memory performance in cognitively intact middle-aged APOE4 carriers. *Cortex* 57: 167–176. doi: 10.1016/j.cortex.2014.04.006

Lozano AM, Fosdick L, Chakravarty MM, Leoutsakos JM, Munro C, Oh E, Drake KE, Lyman CH, Rosenberg PB, Anderson WS, et al. 2016. A Phase II study of fornix deep brain stimulation in mild Alzheimer’s disease. *J Alzheimers Dis* 54: 777–787. doi: 10.3233/JAD-160017

Mann A, Gondard E, Tampellini D, Milsted JAT, Marillac D, Hamani C, Kalia SK, Lozano AM. 2018. Chronic deep brain stimulation in an Alzheimer’s disease mouse model enhances memory and reduces pathological hallmarks. *Brain Stimul* 11: 435–444. doi: 10.1016/j.brs.2017.11.012

Minoshima S, Giordani B, Benet S, Frey KA, Foster NL, Kuhl DE. 1997. Metabolic reduction in the posterior cingulate cortex in very early Alzheimer’s disease. *Ann Neurol* 42: 85–94. doi: 10.1002/ana.410420114

Risberger SL, Saykin AJ, Weid RD, Shen L, Firpi HA, McDonald BC, Alzheimer’s Disease Neuroimaging Initiative (ADNI). 2009. Baseline MRI predictors of conversion from MCI to probable AD in the ADNI cohort. *Curr Alzheimer Res* 6: 347–361. doi: 10.2174/1567205097898929273

Sankar T, Chakravarty MM, Bescos A, Lara M, Obuchi T, Laxton AW, McAndrews MP, Tang-Wai DF, Workman CI, Smith GS, et al. 2015. Deep brain stimulation influences brain structure in Alzheimer’s disease. *Brain Stimul* 8: 645–654. doi: 10.1016/j.brs.2014.11.020

Scharre DW, Weichart E, Nielson D, Zhang J, Agrawal P, Sederberg PB, Knopp MV, Rezai AR, Alzheimer’s Disease Neuroimaging Initiative (ADNI). 2018. Deep brain stimulation of frontal lobe networks to treat Alzheimer’s disease. *J Alzheimers Dis* 62: 621–633. doi: 10.3233/JAD-170082

Schneider AR, Sari Y. 2014. Therapeutic perspectives of drugs targeting Toll-like receptors based on immune physiopathology theory of Alzheimer’s disease. *CNS Neurol Disord Drug Targets* 13: 909–920. doi: 10.2174/18715273166410711093858

Smith GS, de Leon MJ, George AE, Kluger A, Volkow ND, McAue T, Golomb J, Ferris SH, Reisberg B, Ciarravino J, et al. 1992. Topography of cross-sectional and longitudinal glucose metabolic deficits in Alzheimer’s disease. Pathophysiological implications. *Arch Neurol* 49: 1142–1150. doi: 10.1001/archneur.1992.00530350056020

Smith GS, Laxton AW, Tang-Wai DF, McAndrews MP, Diaco- nescu AO, Workman CI, Lozano AM. 2012. Increased cerebral metabolism after 1 year of deep brain stimulation in Alzheimer disease. *Arch Neurol* 69: 1141–1148. doi: 10.1001/archneurol.2012.590

Sperling RA, Dickerson BC, Pihlajamaki M, Vannini P, LaViolette PS, Vitolo OV, Hedden T, Becker JA, Rentz DM, Selko DJ, et al. 2010. Functional alterations in memory networks in early Alzheimer’s disease. *Neuromolecular Med* 12: 27–43. doi: 10.1007/s12017-009-8109-7

Stone SS, Teixeira CM, DeVito LM, Zaalskav K, Josselyn SA, Lozano AM, Frankland PW. 2011. Stimulation of entorhinal cortex promotes adult neurogenesis and facilitates spatial memory. *J Neurosci* 31: 13469–13484. doi: 10.1523/JNEUROSCI.3100-11.2011

Tardif CL, Devenyi GA, Amalar RSC, Pelleuxie S, Poirier J, Rosa-Neto P, Breiter J, Chakravarty MM, PREVENT-AD Research Group. 2018. Regionally specific changes in the hippocampal circuitry accompany progression of cerebrospinal fluid biomarkers in preclinical Alzheimer’s disease. *Hum Brain Mapp* 39: 971–984. doi: 10.1002/hbm.23897

Toda H, Hamani C, Fawcett AP, Hutchison WD, Lozano AM. 2008. The regulation of adult rodent hippocampal neurogenesis by deep brain stimulation. *J Neurosur* 108: 132–138. doi: 10.3171/JNS/2008/108.01.0132

Xia F, Yiu A, Stone SSD, Oh S, Lozano AM, Josselyn SA, Frankland PW. 2017. Entorhinal cortical deep brain stimulation rescues memory deficits in both young and old mice genetically engineered to model Alzheimer’s disease. *Neuropsychopharmacology* 42: 2493–2503. doi: 10.1038/npp.2017.100

Zhang C, Hu WH, Wu DL, Zhang K, Zhang JG. 2015. Behavioral effects of deep brain stimulation of the anterior nucleus of thalamus, entorhinal cortex and fornix in a rat model of Alzheimer’s disease. *Chin Med J (Engl)* 128: 1190–1195. doi: 10.3740/jms/2008/108.01.0132